<DOC>
	<DOCNO>NCT00451932</DOCNO>
	<brief_summary>A proof concept study evaluate safety effectiveness FK778 liver transplant patient .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness FK778 Liver Transplant Patients</brief_title>
	<detailed_description />
	<criteria>Male female patient least 18 year age old 65 year . Female patient child bear potential must negative serum pregnancy test prior enrollment must agree practice effective birth control study . Male patient must agree practice effective birth control method study . Patient recipient primary whole cadaveric liver transplant Patient previously receive receive organ transplant liver . Patient receive ABO incompatible donor liver . Patient donor know HIV positive . Patient current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully . Patient transplant hepatic malignancy single nodule great 5.0 cm diameter 2 nodule least one &gt; 3.0 cm . Patient serum creatinine &gt; 175 Âµmol/L baseline . Patient uncontrolled concomitant infection and/or severe diarrhoea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer unstable medical condition could interfere study objective . Patient receiving may require warfarin fluvastatin study . Patient participate another clinical trial and/or take take investigational drug 28 day prior transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Malononitrilamide</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>treatment efficacy</keyword>
	<keyword>treatment effectiveness</keyword>
</DOC>